Therapeutics - Lectures

A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors

Proffered Paper Session

Antiretroviral therapy for the prevention of HIV: where are we now and where are we going?

Special Plenary Session

The potential impact of HPV vaccines

Head and neck HPV associated cancer: State of the art

BONE MARROW STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS

New Players in MS

Initial Results from the SAPHIRE Study: a Phase II Trial with the Novel Oral Histone Deacetylase (HDAC) Inhibitor Resminostat in Relapsed or Refractory Hodgkin Lymphoma Patients

New Drugs

Extended Follow-Up of the Safety of 131I Radiolabelled Anti-CD25 Antibody, Basiliximab, in Patients with CD25-Positive, Refractory Hodgkin Lymphoma

New Drugs

LBH-589

New Drugs

SGN-35

New Drugs

Modern cancer drugs - will they be affordable in the future?

Cancer Prevention and Health Politics: Economical and other Controversies

Severe hypoalbuminemia in a patient with long duration Crohn's disease treated with Infliximab

Challenging Cases

Long- term outcome of treatment with infliximab in paediatric Crohn's disease : a population-based study

Safety in IBD therapy

Deep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn’s disease: Results from EXTEND

It's not always IBD

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis

Extraintestinal manifestations